Obesity management has evolved with newer pharmacologic therapies demonstrating meaningful efficacy, yet safety and tolerability remain central to treatment selection. Adverse effects, patient preferences, and long-term adherence all influence whether a treatment is started, continued, or switched in routine practice.

Gastrointestinal adverse events are among the most commonly reported considerations with current pharmacologic therapies for obesity, including nausea, vomiting, and diarrhea. These effects are often mild to moderate and more frequent during dose escalation, but they can still affect treatment persistence. Safety profiles vary across therapeutic classes, and clinicians must also consider less common adverse events, such as gastrointestinal complications or gallbladder-related events, as well as class-specific considerations that may require monitoring.

Patient factors should guide therapy choice, including comorbidities, prior treatment experience, weight-loss goals, and the likelihood of sustained adherence. In practice, the most appropriate option is often the one that best balances efficacy with an acceptable safety profile for the individual patient.

How do you weigh efficacy versus tolerability when selecting pharmacologic therapies for obesity? What patient factors most influence your decision to initiate or switch treatment in obesity management?

Patient Background:

Mr. C is a 52-year-old male with a BMI of 37 kg/m² and a 10-year history of obesity with multiple prior attempts at sustained weight loss through calorie restriction and exercise.

Comorbidities include hypertension (amlodipine 10 mg), dyslipidemia (atorvastatin 40 mg), prediabetes (HbA1c 6.2%), and obstructive sleep apnea managed with CPAP. He is a non-smoker. Family history includes paternal myocardial infarction at age 58. He is motivated for pharmacologic intervention and has enrolled in a structured lifestyle program.

Assessment & Diagnosis:

Waist circumference: 116 cm. BP: 138/86 mmHg. Fasting glucose: 108 mg/dL. LDL-C: 118 mg/dL.…read more

1. Please provide a minimum of a 3 sentence response.
2. 1.Which comorbidities support GLP-1 RA therapy in this patient?
3. 2.What counseling strategies help minimize GI adverse effects during GLP-1 RA dose escalation?

Show Less

Erik Nelson, PhD, Professor at the University of Illinois Urbana-Champaign and Basic Science Chair for ENDO 2026, highlighted research involving cholesterol regulation and the evolution of GLP-1/GIP agonist therapies for diabetes and obesity. He also discussed their reported cardiovascular benefits and other areas of ongoing investigation. Micah Eimer, MD, General Cardiologist at Northwestern Medicine in Chicago, presented a study examining hypotension among patients who initiated GLP-1–based therapy while taking antihypertensive medications. His observations highlight the importance of monitoring low blood pressure, falls, and fainting in this clinical setting.